Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Psychiatry
Published in: BMC Psychiatry 1/2020

Open Access 01-12-2020 | Schizophrenia | Research article

The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index

Authors: Daniel Schöttle, Wolfgang Janetzky, Daniel Luedecke, Elmar Beck, Christoph U. Correll, Klaus Wiedemann

Published in: BMC Psychiatry | Issue 1/2020

Login to get access

Abstract

Background

In this non-interventional study, the functionality and well-being of patients with schizophrenia with aripiprazole once-monthly (AOM) was evaluated under real-life conditions in a naturalistic population.

Methods

This non-interventional, prospective, multicenter 6-month study included 242 predominantly symptomatically stable patients (mean age 43.1 ± 15.1 years, 55% male) who switched their treatment to AOM after 9.7 (± 22.3) months of oral treatment. Outcome parameters included functionality (Global Assessment of Functioning, GAF), patient’s wellbeing (WHO-5 Well-Being Index, WHO-5), and both patient’s and clinician’s assessment of efficacy and tolerability of AOM. Treatment emergent adverse events (TRAE) were also recorded.

Results

At baseline, the mean GAF score was 47.0 (±13.9), indicating that patients experienced serious impairment in functioning. A continuous increase to 60.2 (±17.0) during treatment was found, with a robust and significant increase already after 4 weeks. At study start, patients reported diminished wellbeing, with a mean score of 10.6 (±5.6) on the WHO-5 scale. During treatment, patient wellbeing increased continuously with strong and significant improvements even after 4 weeks and an overall improvement of 4.8 (±6.9) over the course of 6 months with an endpoint of 15.4 (±5.5). Stratification of these results showed that more pronounced effects were achieved in younger patients ≤35 years (p<0.05 for GAF). The effectiveness and tolerability of AOM was rated good/very good by most patients (89.2 and 93.7%) and physicians (91.4 and 96.8%). Only few TRAEs occurred.

Conclusions

Our results show a significant positive effect after initiation of AOM treatment in predominantly stable patients with schizophrenia on their functioning and wellbeing, which was even more pronounced in patients aged ≤35 years, thereby supporting previous randomized controlled findings under routine conditions in clinical practice.
Literature
1.
Kahn RS, Sommer IE, Murray RM, Meyer-Lindenberg A, Weinberger DR, Cannon TD, et al. Schizophrenia. Nat Rev Dis Primers. 2015;1:15067.PubMedCrossRef
2.
Emsley R, Chiliza B, Asmal L. The evidence for illness progression after relapse in schizophrenia. Schizophr Res. 2013;148(1–3):117–21.PubMedCrossRef
3.
Lieberman JA, Jarskog LF, Malaspina D. Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. J Clin Psychiatry. 2006;67(6):983–90.PubMedCrossRef
4.
Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–60.PubMedPubMedCentralCrossRef
5.
Valenstein M, Ganoczy D, McCarthy JF, Myra Kim H, Lee TA, Blow FC. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry. 2006;67(10):1542–50.PubMedCrossRef
6.
Wade M, Tai S, Awenat Y, Haddock G. A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev. 2017;51:75–95.PubMedCrossRef
7.
Phan SV. Medication adherence in patients with schizophrenia. Int J Psychiatry Med. 2016;51(2):211–9.PubMedCrossRef
8.
Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness. Patient Prefer Adherence. 2017;11:449–68.PubMedPubMedCentralCrossRef
9.
Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–9.PubMedCrossRef
10.
Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 2013 Oct;74(10):957–65.PubMedCrossRef
11.
Taipale H, Mehtälä J, Tanskanen A, Tiihonen J. Comparative effectiveness of antipsychotic drugs for Rehospitalization in schizophrenia-a Nationwide study with 20-year follow-up. Schizophr Bull. 2018;44(6):1381–7.PubMedCrossRef
12.
13.
Di Lorenzo R, Ferri P, Cameli M, Rovesti S, Piemonte C. Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting. Neuropsychiatr Dis Treat. 2019;15:183–98.PubMedPubMedCentralCrossRef
14.
Kishimoto T, Hagi K, Nitta M, Leucht S, Olfson M, Kane JM, et al. Effectiveness of long-acting injectable vs Oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull. 2018 Apr 6;44(3):603–19.PubMedCrossRef
15.
Naber D, Hansen K, Forray C, Baker RA, Sapin C, Beillat M, et al. Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.PubMedCrossRef
16.
Naber D, Baker RA, Eramo A, Forray C, Hansen K, Sapin C, et al. Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study. Schizophr Res. 2018;192:205–10.PubMedCrossRef
17.
Potkin SG, Loze J-Y, Forray C, Baker RA, Sapin C, Peters-Strickland T, et al. Multidimensional assessment of functional outcomes in schizophrenia: results from QUALIFY, a head-to-head trial of Aripiprazole once-monthly and Paliperidone Palmitate. Int J Neuropsychopharmacol. 2017;20(1):40–9.PubMed
18.
Arques-Egea S, Ros-Cucurull E, Iranzo-Tatay C, Parro-Torres C, Palma-Álvarez RF, Castrillo E, et al. 95 differential aspects between schizophrenia treatment approaches: Oral antipsychotics vs Aripiprazole long-acting injectable. CNS Spectr. 2019;24(1):221–2.CrossRef
19.
Kane JM, Sanchez R, Perry PP, Jin N, Johnson BR, Forbes RA, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617–24.PubMedCrossRef
20.
Fleischhacker WW, Sanchez R, Perry PP, Jin N, Peters-Strickland T, Johnson BR, et al. Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br J Psychiatry. 2014;205(2):135–44.PubMedCrossRef
21.
Fleischhacker WW, Baker RA, Eramo A, Sanchez R, Tsai L-F, Peters-Strickland T, et al. Effects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studies. Schizophr Res. 2014;159(2–3):415–20.PubMedCrossRef
22.
Schaub D, Brüne M, Bierhoff H-W, Juckel G. Comparison of self- and clinician’s ratings of personal and social performance in patients with schizophrenia: the role of insight. Psychopathology. 2012;45(2):109–16.PubMedCrossRef
23.
Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88.PubMedCrossRef
24.
Karow A, Wittmann L, Schöttle D, Schäfer I, Lambert M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci. 2014;16(2):185–95.PubMedPubMedCentral
25.
Priebe S, Gruyters T, Heinze M, Hoffmann C, Jäkel A. Subjective evaluation criteria in psychiatric care--methods of assessment for research and general practice. Psychiatr Prax. 1995;22(4):140–4.PubMed
26.
Ruggeri M, Nosè M, Bonetto C, Cristofalo D, Lasalvia A, Salvi G, et al. Changes and predictors of change in objective and subjective quality of life: multiwave follow-up study in community psychiatric practice. Br J Psychiatry. 2005;187:121–30.PubMedCrossRef
27.
Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K. Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study. BMC Psychiatry. 2018;18(1):365.PubMedPubMedCentralCrossRef
28.
Amri I, Millier A, Toumi M. Minimum clinically important difference in the global assessment functioning in patients with schizophrenia. Value Health. 2014;17(7):A765–6.PubMedCrossRef
29.
Topp CW, Østergaard SD, Søndergaard S, Bech P. The WHO-5 well-being index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167–76.PubMedCrossRef
30.
Bhapkar VP. A note on the equivalence of two test criteria for hypotheses in categorical data. J Am Stat Assoc. 1966;61(313):228.CrossRef
31.
Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, et al. Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study. BMC Psychiatry. 2019;19(1):114.PubMedPubMedCentralCrossRef
32.
de Diego BOP G, SLR G. 64 Aripiprazole Long-acting Injectable in Schizophrenia. An 18-month Follow-up and Mirror-image Study. CNS Spectr. 2019;24(1):209–10.CrossRef
33.
Messer T, Schmauß M, Spevakne-Goeroecs T, Kungel M, Ebrecht M, Werner C, et al. Clinical use of aripiprazole in patients with schizophrenia: a real-life setting results from the German Postmarketing surveillance study. World J Biol Psychiatry. 2010;11(2–2):231–8.PubMedCrossRef
34.
Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand. 2006;113(2):148–53.PubMedCrossRef
35.
36.
Montemagni C, Frieri T, Rocca P. Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life. Neuropsychiatr Dis Treat. 2016;12:917–29.PubMedPubMedCentral
37.
Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Fernández-Rodríguez M, Vázquez-Bourgon J, Suárez-Pinilla P, et al. 44 real world effectiveness: a 6-month naturalistic follow-up study of schizophrenia patients after switching to Aripiprazole monohydrate (AOM) treatment. CNS Spectr. 2019;24(1):199–200.CrossRef
38.
Suzuki T, Uchida H, Sakurai H, Ishizuki T, Tsunoda K, Takeuchi H, et al. Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. Psychiatry Res. 2015;227(2–3):265–9.PubMedCrossRef
39.
Girardi P, Del Casale A, Rapinesi C, Kotzalidis GD, Splendori F, Verzura C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Hum Psychopharmacol. 2018;33(3):e2658.PubMedCrossRef
40.
Wu S-FV. Rapid screening of psychological well-being of patients with chronic illness: reliability and validity test on WHO-5 and PHQ-9 scales. Depress Res Treat. 2014;2014:239490.PubMedPubMedCentral
41.
Ritsner M, Gibel A, Perelroyzen G, Kurs R, Jabarin M, Ratner Y. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24(6):582–91.PubMedCrossRef
42.
Mortimer AM, Al-Agib AOA. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int J Soc Psychiatry. 2007;53(2):99–107.PubMedCrossRef
43.
Vothknecht S, Schoevers RA, de Haan L. Subjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. Aust N Z J Psychiatry. 2011;45(3):182–92.PubMedCrossRef
44.
Awad AG, Voruganti LNP. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27(8):625–36.PubMedCrossRef
45.
Stahl SM. Long-acting injectable antipsychotics: shall the last be first? CNS Spectr. 2014;19(1):3–5.PubMedCrossRef
46.
Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–26.PubMedPubMedCentralCrossRef
47.
de Haan L, van Bruggen M, Lavalaye J, Booij J, Dingemans PMAJ, Linszen D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303–9.PubMedCrossRef
48.
de Haan L, Lavalaye J, van Bruggen M, van Nimwegen L, Booij J, van Amelsvoort T, et al. Subjective experience and dopamine D2 receptor occupancy in patients treated with antipsychotics: clinical implications. Can J Psychiatr. 2004;49(5):290–6.CrossRef
49.
Bressan RA, Costa DC, Jones HM, Ell PJ, Pilowsky LS. Typical antipsychotic drugs -- D (2) receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res. 2002;56(1–2):31–6.PubMedCrossRef
50.
Mizrahi R, Mamo D, Rusjan P, Graff A, Houle S, Kapur S. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics. Int J Neuropsychopharmacol. 2009;12(5):715–21.PubMedCrossRef
51.
Yan T, Greene M, Chang E, Hartry A, Touya M, Broder MS. Medication adherence and discontinuation of Aripiprazole once-monthly 400 mg (AOM 400) versus Oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612–25.PubMedPubMedCentralCrossRef
52.
Taylor DM, Sparshatt A, Amin F, Osborne I, Dzahini O, Hughes G, et al. Aripiprazole long-acting injection - a mirror image study of its effects on hospitalisation at one year. J Psychopharmacol. 2017;31(12):1564–9.PubMedCrossRef
53.
Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1–24.PubMedCrossRef
54.
Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a Nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–93.PubMedPubMedCentralCrossRef
55.
Fagiolini A, Aguglia E, Ballerini A, Callista G, Carpiniello B, Clerici M, et al. Real-world effectiveness of long acting aripiprazole: treatment persistence and its correlates in the Italian clinical practice. Psychiatry Res. 2019;272:698–706.PubMedCrossRef
56.
Mallikaarjun S, Kane JM, Bricmont P, McQuade R, Carson W, Sanchez R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–8.PubMedCrossRef
57.
Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–60.PubMedCrossRef
58.
Peters-Strickland T, Baker RA, McQuade RD, Jin N, Eramo A, Perry P, et al. Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study. NPJ Schizophr. 2015;1:15039.PubMedPubMedCentralCrossRef
59.
Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia--a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1–3):83–92.PubMedCrossRef
60.
Haddad PM, Tiihonen J, Haukka J, Taylor M, Patel MX, Korhonen P. The place of observational studies in assessing the effectiveness of depot antipsychotics. Schizophr Res. 2011;131(1–3):260–1.PubMedCrossRef
61.
Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013;66(8 Suppl):S37–41.PubMedPubMedCentralCrossRef
62.
Ishigooka J, Nakamura J, Fujii Y, Iwata N, Kishimoto T, Iyo M, et al. Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr Res. 2015;161(2–3):421–8.PubMedCrossRef
Metadata
Title
The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index
Authors
Daniel Schöttle
Wolfgang Janetzky
Daniel Luedecke
Elmar Beck
Christoph U. Correll
Klaus Wiedemann
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2020
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-020-02488-1

Other articles of this Issue 1/2020

BMC Psychiatry 1/2020 Go to the issue

Research article

Cortisol and DHEA-S levels in pregnant women with severe anxiety

Research article

A meta-analysis of depressive symptoms among Ethiopian prisoners and a narrative description of its associated factors: a country based systematic review and meta-analysis study

Research article

Recovery services and expectation of consumers and mental health professionals in community-based residential facilities of Ghana

Research article

Attitudes towards psychopharmacology and psychotherapy in psychiatric patients with and without migration background

Research article

Workplace experiences of mental health consumer peer workers in New South Wales, Australia: a survey study exploring job satisfaction, burnout and turnover intention

Research article

Using EMDR therapy with patients in an acute mental health crisis